EQL Pharma
OM:EQL Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 2 Fair Values set on narratives written by author
MA
Mandelman
Community Contributor
EQL Pharma aiming for 19% Revenue Growth in 5 Years
Catalysts Recurring Cash Flow: EQL’s core generic product delivers near‐“infinite” cash flow, thanks to its essential role in healthcare. Market Niche & Protection: Its product is too small for major competitors to challenge, ensuring a stable, low‐competition environment.
View narrativeSEK 77.65
FV
7.9% overvalued intrinsic discount19.00%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
New narrative